Evaluation of "increased" hemoglobin in the JAK2 mutations era: A diagnostic algorithm based on genetic tests

Mayo Clinic Proceedings

Volumn 82, Issue 5, 2007, Pages 599-604

  Tefferi, Ayalew ^a   Pardanani, Animesh ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BLOOD; BONE MARROW EXAMINATION; DIAGNOSTIC PROCEDURE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MEASUREMENT; PATHOGENESIS; POLYCYTHEMIA VERA;

EID: 34248146662     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.5.599     Document Type: Article

References (58)

1. Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C. Hematological and iron-related analytes - reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11. 2005; 247:1-156.
2. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006 Mar 1;107:1747-1750. Epub 2005 Sep 27.
3. V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80:947-958.
4. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
5. Tefferi A. JAK2 mutations in polycythemia vera - molecular mechanisms and clinical applications. N Engl J Med. 2007;356:444-445.
6. Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80;1220-1232.
7. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood. 1995;86:15-22.
8. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002 Dec;32:614-621. Epub 2002 Nov 4.
9. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 2006 Jan 17;103:654-659. Epub 2006 Jan 9.
10. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.
11. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40:52-57.
12. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409.
13. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
14. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
15. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662-2667.
16. Murati A, Gelsi-Boyer V, Adelaide J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation [letter]. Leukemia. 2005;19:1692-1696.
17. Bousquet M, Quelen C, De Mas V, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene. 2005;24:7248-7252.
18. Adelaide J, Perot C, Gelsi-Boyer V, et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma [letter]. Leukemia. 2006;20:536-537.
19. Griesinger F, Hennig H, Hillmer F, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer. 2005;44:329-333.
20. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [published correction appears in Lancet. 2005;366:122]. Lancet. 2005; 365:1054-1061.
21. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
22. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
23. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
24. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006 Oct 1;108:2435-2437. Epub 2006 Jun 13.
25. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Aug 15; 106:1207-1209. Epub 2005 Apr 28.
26. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005 Sep 15;106:2162-2168. Epub 2005 May 26.
27. Melzner I, Weniger MA, Menz CK, Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma [letter]. Leukemia. 2006;20:157-158.
28. Lee JW, Soung YH, Kim SY, et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma. 2006;47:313-314.
29. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia [letter]. Br J Haematol. 2005;130:964-965.
30. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 17;106:3377-3379. Epub 2005 Aug 4.
31. Lee JW, Soung YH, Kim SY, et al. Absence of JAK2 V617F mutation in gastric cancers [letter]. Acta Oncol. 2006;45:222-223.
32. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25:1434-1436.
33. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders [letter]. Blood. 2005;106:2920-2921.
34. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005;131:166-171.
35. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005 Nov 15;106:3374-3376. Epub 2005 Aug 4.
36. McClure RF, Hoyer JD, Mai M. The JAK2 V617F mutation is absent in patients with erythrocytosis due to high oxygen affinity hemoglobin variants. Hemoglobin. 2006;30:487-489.
37. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. A. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006 Jul 1;108:346-352. Epub 2006 Mar 14.
38. Pastore YD, Jelinek J, Ang S, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood. 2003 Feb 15;101:1591-1595. Epub 2002 Oct 10.
39. Cario H, Schwarz K, Jorch N, et al. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica. 2005;90:19-24.
40. Percy MJ, McMullin MF, Jowitt SN, et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood. 2003 Aug 1;102:1097-1099. Epub 2003 Apr 17.
41. Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia [published correction appears in Am J Hum Gen. 2004;74:598]. Am J Hum Genet. 2003 Aug;73:412-419. Epub 2003 Jul 3.
42. Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood. 2006 Jan 15;107:514-519. Epub 2005 Oct 6.
43. Gordeuk VR, Sergueeva AI, Miasnikova GY et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004 May 15;103:3924-3932. Epub 2004 Jan 15.
44. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2007;28:143-149.
45. Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood. 2002;99:3562-3565.
46. Karasawa Y, Sakaguchi M, Minami S, et al. Duodenal somatostatinoma and erythrocytosis in a patient with von Hippel-Lindau disease type 2A. Intern Med. 2001;40:38-43.
47. Bento MC, Chang KT, Guan Y, et al. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients [letter]. Haematologica. 2005;90:128-129.
48. Randi ML, Murgia A, Putti MC, et al. Low frequency of VHL gene mutations in young individuals with polycythemia and high serum erythropoietin [letter]. Haematologica. 2005;90:689-691.
49. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 1990;348:647-649.
50. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993;90:4495-4499.
51. Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 1997;89:4628-4635.
52. Arcasoy MO, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27:63-74.
53. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF. Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997; 90:2057-2061.
54. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194-1198.
55. Jones RT, Shih TB. Hemoglobin variants with altered oxygen affinity. Hemoglobin. 1980;4:243-261.
56. Hoyer JD, Allen SL, Beutler E, Kubik K, West C, Fairbanks VF. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucoses-phosphate dehydrogenase (G-6-PD) deficiency. Am J Hematol. 2004; 75:205-208.
57. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/ erythrocytoses. Haematologica. 2005;90:109-116.
58. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28:57-62.